Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast, this time chatting to managing director, Michael Thurn.

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode Tim chats with Dr Michael Thurn, Managing Director at PharmAust (ASX:PAA).

PharmAust recently submitted a request for orphan medicinal product designation (OMPD) to the European Medicines Agency (EMA) for its lead drug monepantel for the treatment of amyotrophic lateral sclerosis (ALS).

Monepantel, originally for veterinary use, has shown potential in slowing ALS progression.

The drug is currently in a clinical development phase, and PharmAust is preparing to enter an adaptive Phase 2/3 clinical trial in the United States which is expected to commence in late 2024.

Like to tune in through another app? Just search for Health Kick Podcast with Tim Boreham and subscribe!

This podcast was developed in collaboration with PharmAust, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Health Kick Podcast: PharmAust in the fight against MND and ALS with lead drug monepantel